The Lessons of Asilomar for Today’s Science
By Alexander Capron,
The New York Times
| 05. 28. 2015
Untitled Document
There is a precedent for establishing internationally agreed-upon limits for new science, though it can be hard to do.
In 1973, scientists who were using novel molecular techniques to splice DNA between different organisms asked the National Academy of Sciences to consider the potential hazards as they might affect the public. In July 1974, an Academy-appointed committee publicly called for a large category of experiments to be suspended until leaders in the field could plan a way forward. Such a self-imposed moratorium on basic research was unprecedented, but it worked.
A hundred and fifty scientists and physicians from around the world gathered in February 1975 at the Asilomar conference center near Monterey, California, in what one scientist termed an amazing show of “self denial and social responsibility in the face of strong intellectual temptation” to continue the experiments.
The outcome of the meeting was equally impressive. Categories of experiments were graded by their riskiness: Some were deemed excessively dangerous and kept off-limits, while others were to be allowed once the appropriate biological and physical means of risk-containment had...
Related Articles
By Jason Liebowitz, The New Yorker | 03.06.2026
When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after...
By Émile P. Torres, Truthdig | 02.26.2026
It’s well known that Jeffrey Epstein was a super-wealthy pedophile with an extraordinary network of powerful friends: tech billionaires, politicians and academics. But few people know that he was also a transhumanist — someone who believes that we should...
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...